Last $44.29 USD
Change Today 0.00 / 0.00%
Volume 0.0
PKI On Other Exchanges
New York
As of 8:04 PM 01/23/15 All times are local (Market data is delayed by at least 15 minutes).

perkinelmer inc (PKI) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/3/14 - $48.26
52 Week Low
10/15/14 - $38.96
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for PERKINELMER INC (PKI)

perkinelmer inc (PKI) Related Businessweek News

No Related Businessweek News Found

perkinelmer inc (PKI) Details

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, research, environmental, industrial, and laboratory services markets worldwide. The company operates through two segments, Human Health and Environmental Health. The Human Health segment develops diagnostics, tools, and applications to help detect diseases earlier, and to accelerates the discovery and development of critical new therapies. This segment provides early detection for genetic disorders from pre-conception to early childhood, as well as offers digital x-ray flat panel detectors and infectious disease testing for the diagnostics market; and a suite of solutions, such as reagents, liquid handling, and detection and imaging technologies that enable researchers to improve the drug discovery process. Its research portfolio includes instrumentation for automation and detection solutions, in vitro and in vivo imaging and analysis hardware and software, and a portfolio of consumable products, including drug discovery and research reagents. The Environmental Health segment provides services and solutions to facilitate the creation of safer food and consumer products, secure surroundings, and efficient energy resources. This segment offers analytical technologies, solutions, and services that enable its customers to understand the health aspects of environment, including air, water, soil, and food; analytical instrumentation for the industrial market that comprise the chemical, petrochemical, lubricant, electronics, semiconductor, and quality assurance industries; and laboratory services. The company markets its products and services under various brands directly through its own sales force. Its customers include pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1931 and is headquartered in Waltham, Massachusetts.

7,409 Employees
Last Reported Date: 11/4/14
Founded in 1931

perkinelmer inc (PKI) Top Compensated Officers

Chairman, Chief Executive Officer, President ...
Total Annual Compensation: $978.3K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $469.6K
Senior Vice President and President of Human ...
Total Annual Compensation: $341.0K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $394.6K
Compensation as of Fiscal Year 2013.

perkinelmer inc (PKI) Key Developments

PerkinElmer, Inc. Declares Regular Quarterly Dividend, Payable on May 11, 2015

The Board of Directors of PerkinElmer Inc. declared a regular quarterly dividend of $0.07 per share of common stock on January 23, 2015. This dividend is payable on May 11, 2015 to all shareholders of record at the close of business on April 17, 2015.

PerkinElmer Opens Suzhou PerkinElmer Medical Laboratory Co., Ltd. in China

PerkinElmer Inc. has opened Suzhou PerkinElmer Medical Laboratory Co. Ltd. in China. This new facility provides a comprehensive offering of lab services to hospitals and patients in China, supporting the prevention of birth defects in newborns and infectious disease in adults. The Suzhou PerkinElmer Medical Laboratory extends the Company's solutions to include an expanded range of lab services for customers and patients, including molecular cytogenetics detection, screening for inherited metabolic diseases (IMDs), and viral loads testing. The Suzhou PerkinElmer Medical Laboratory also serves as a venue for academics and clinical medical doctors to perform scientific R&D, collaborate and train colleagues, and transform medical research into the development of new technologies for clinical use. In addition, PerkinElmer plans to expand its menu of services in the lab to include a series of tumor testing, as well as introduce new applications based on molecular cytogenetic platforms such as sequencing technology.

PerkinElmer Inc. Announces Availability of Screening Test for SCID in US and Canada

PerkinElmer Inc. has announced the availability of screening test in the US and Canada for severe combined immunodeficiency, or SCID, also known more commonly as bubble boy disease. PerkinElmer has received market authorization from the FDA and from Health Canada to offer the VICTOR EnLite and EnLite Neonatal TREC Kit. Since 2013, PerkinElmer's SCID screening test has been available for sale in select countries in Europe and the Middle East, introduced under CE marking. With the approval of this test in the US and Canada, PerkinElmer now provides SCID screening in more than 30 countries worldwide.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PKI:US $44.29 USD 0.00

PKI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Getinge AB kr183.50 SEK +1.30
QIAGEN NV €20.98 EUR +0.049
Sirona Dental Systems Inc $92.07 USD +0.17
STERIS Corp $66.18 USD +0.17
Teleflex Inc $111.71 USD +0.51
View Industry Companies

Industry Analysis


Industry Average

Valuation PKI Industry Range
Price/Earnings 25.6x
Price/Sales 2.2x
Price/Book 2.4x
Price/Cash Flow 25.8x
TEV/Sales 1.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PERKINELMER INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at